Gil M. Labrucherie, CFA, J.D., is the Chief Financial Officer at SEPTERNA INC., a biotechnology company pioneering advanced therapies for unmet medical needs. With more than 25 years of experience at the intersection of finance, law, and life sciences, Gil earned his J.D. from Stanford Law School and later obtained his Chartered Financial Analyst designation. His early career included practicing corporate law at a top-tier firm in Silicon Valley, where he advised on mergers, acquisitions, and venture financings for emerging biotech firms, honing his expertise in regulatory compliance and capital markets. Before joining SEPTERNA INC. in 2020, Gil served as Vice President of Finance at a prominent venture-backed pharmaceutical company, leading a $300 million Series C funding round and optimizing operations to achieve profitability ahead of schedule. His notable achievements include structuring over $1 billion in strategic partnerships and debt financings across his career, as well as implementing enterprise risk management frameworks that mitigated financial exposures during market volatility. Recognized as a Fellow of the CFA Institute, Gil has also authored publications on biotech valuation and spoken at industry conferences on sustainable growth strategies. At SEPTERNA INC., Gil oversees all financial operations, including treasury, investor relations, and strategic planning, playing a pivotal role in the company's expansion through clinical trial advancements and international market entry. Under his leadership, SEPTERNA has strengthened its balance sheet, secured key grants from government agencies, and positioned itself for upcoming milestones in drug development pipelines. Gil's strategic vision continues to fuel SEPTERNA's mission to deliver transformative therapies to patients worldwide.